IKBKB and asthma: In relation to IKKβ-mediated canonical NF-κB signalling, concerted efforts have been made to develop several selective small-molecule kinase inhibitors of IKKβ [16,17,18] primarily focused on delivering clinical agents to treat inflammatory conditions such as asthma, arthritic disease, and gastrointestinal conditions [3,19,20].